Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant
France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative for both the biotech and the US and European licensee, Roivant Sciences.
You may also be interested in...
Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.